Commencement of the project to develop a COVID-19 test with the University of Sheffield Further to the announcement dated 6 May 2020, the Company announced that Paraytec Limited (“Paraytec”), a
London / Vancouver: June 1, 2020 – Mkango Resources Ltd. (AIM/TSX-V: MKA) (the “Company” or “Mkango”) is pleased to announce the donation of a new state of the art Mindray
Share Talk caught up with Manchester-based company Genedrive PLC and spoke with David Budd, CEO about the company recent announcement with the development of two coronavirus tests, one for central
Expansion to encompass RNA interference (RNAi) as a new therapeutic modality and the formation of a Scientific Advisory Board (SAB)
Further to the Company’s announcement on 16 April 2020, N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is
4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, is pleased to announce the final results for the Group for the year ended 31 December
Tiziana Lifesciences Announces Intention to Demerge Its StemPrintER Genomics-Based Personalized Medicine Business as a Separate Listed Company
Open Orphan Plc (LON: ORPH), a rapidly growing specialist pharmaceutical services company which has a focus on orphan drugs and is the world leader in the testing of vaccines and
New COVID-19 testing programme to assist employers with return-to-work process and workforce safety
Braveheart (AIM: BRH), the fund management and strategic investment group, is pleased to announce that it has conditionally acquired 22,145 shares in Phasefocus Holdings Limited (“Phasefocus”) from Synergy Investments Limited
Global, exclusive, direct-to-consumer sales and marketing agreement for COVID-19 self-testing
